A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer-Reference-Cited by-同舟云学术

A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer

Published:2013-12 Issue:3 Volume:82 Page:441-448
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Reck Martin,Krzakowski Maciej,Chmielowska Ewa,Sebastian Martin,Hadler Dietrich,Fox Tara,Wang Qiang,Greenberg Jon,Beckman Robert A.,von Pawel Joachim

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

2. Cancer statistics, 2007;Jemal;CA Cancer J Clin,2007

3. The 2004 World Health Organization classification of lung tumors;Beasley;Semin Roentgenol,2005

4. Revisions in the International System for Staging Lung Cancer;Mountain;Chest,1997

5. Multidisciplinary management of lung cancer;Spira;N Engl J Med,2004

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innate immune cells: Key players of orchestra in modulating tumor microenvironment (TME);Heliyon;2024-03

2. Current and future prospective of caspases targeting in cancer therapy;Caspases as Molecular Targets for Cancer Therapy;2024

3. Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy;Cells;2022-11-22

4. TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status;Cancers;2022-10-26

5. Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges;Frontiers in Immunology;2021-08-20